Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

por Daud, A. I., Xu, C., Hwu, W.-J., Urbas, P., Andrews, S., Papadopoulos, N. E., Floren, L. C., Yver, A., DeConti, R. C., Sondak, V. K.
Publicado 2010

Phase II trial of imatinib mesylate in patients with metastatic melanoma

por Kim, K B, Eton, O, Davis, D W, Frazier, M L, McConkey, D J, Diwan, A H, Papadopoulos, N E, Bedikian, A Y, Camacho, L H, Ross, M I, Cormier, J N, Gershenwald, J E, Lee, J E, Mansfield, P F, Billings, L A, Ng, C S, Charnsangavej, C, Bar-Eli, M, Johnson, M M, Murgo, A J, Prieto, V G
Publicado 2008